Scenic enters license and research agreement with alnylam

Amsterdam, the netherlands, august 26, 2025 – scenic biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with alnylam pharmaceuticals, inc. (nasdaq: alny) to leverage scenic's cell-seq platform for discovering novel targets for rnai therapeutics.

ALNY Ratings Summary

ALNY Quant Ranking